|1.||Li, Benyi: 2 articles (06/2012 - 06/2011)|
|2.||Wrightson, Emma: 1 article (01/2015)|
|3.||Shepherd, Peter R: 1 article (01/2015)|
|4.||Sweetlove, Melanie: 1 article (01/2015)|
|5.||Rewcastle, Gordon W: 1 article (01/2015)|
|6.||Kolekar, Sharada: 1 article (01/2015)|
|7.||Jamieson, Stephen M F: 1 article (01/2015)|
|8.||Baguley, Bruce C: 1 article (01/2015)|
|9.||Peng, Yi-Fan: 1 article (11/2014)|
|10.||Pan, Hong-Da: 1 article (11/2014)|
|1.||Prostatic Neoplasms (Prostate Cancer)
06/04/2012 - "Recent studies showed that TGX-221 has antiproliferative activity against PTEN-deficient tumor cell lines including prostate cancers. "
06/06/2011 - "The objective of this present study is to develop a peptide-drug conjugate to specifically deliver TGX-221 to HER2 overexpressing prostate cancer cells. "
06/04/2012 - "Prodrug strategy for PSMA-targeted delivery of TGX-221 to prostate cancer cells."
06/06/2011 - "TGX-221 is a highly potent phosphoinositide 3-kinase β (PI3Kβ) inhibitor that holds great promise as a novel chemotherapeutic agent to treat prostate cancer. "
|2.||Colorectal Neoplasms (Colorectal Cancer)
11/21/2014 - "In vitro, PIK3CB expression was upregulated in all four colorectal cancer cell lines concurrently treated with 6-Gy ionizing radiation, and the PIK3CB-specific inhibitor TGX-221 effectively inhibited the clonogenic formation of these four colorectal cancer cell lines. "
11/21/2014 - "Pharmacological assays were used to evaluate the therapeutic relevance of TGX-221 (a PIK3CB-specific inhibitor) in the four colorectal cancer cell lines. "
|4.||Melanoma (Melanoma, Malignant)
01/01/2015 - "Here, a panel of nine low-passage human metastatic melanoma cell lines with BRAF mutations was tested in cell proliferation and protein expression assays for sensitivity to inhibitors of MEK (selumetinib) and BRAF (vemurafenib) as single agents and in combination with inhibitors of pan-PI3K (ZSTK474), pan-PI3K/mTOR (BEZ235), individual PI3K isoforms (p110α, A66; p110β, TGX-221; p110γ, AS-252424; p110δ, idelalisib), or mTORC1/2 (KU-0063794). "
06/01/2011 - "The novel finding of a clear impact on hemostasis by TGX-221 was demonstrated by increased bleeding in two models in mice at anti-thrombotic doses. "
06/01/2011 - "TGX-221 is a selective PI3K-β inhibitor with a good separation of anti-thrombotic efficacy and bleeding (therapeutic index) in rats. "
|1.||Protein Isoforms (Isoforms)
|2.||5- (5- (4- fluoro- 2- hydroxyphenyl)furan- 2- ylmethylene)thiazolidine- 2,4- dione
|4.||5- quinoxalin- 6- ylmethylenethiazolidine- 2,4- dione